$51.20
-0.35-0.68%
Last update: Nov 10, 4:00 PM
Enliven Therapeutics Inc
ELVNNASDAQ
Enliven Therapeutics rose 175.5% from $18.71 to $51.55, ahead of the S&P 500's +10.0%. Its worst day was Dec 12 (−10.2%), and its low came Jan 6 at $15.14.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.32 beat the $-0.45 estimate on $0.00 revenue.
−0.1% · S&P 500 −1.7%
Enliven Therapeutics closed at its lowest level of the year, 19.1% below where the year started.
Story events cover the past 12 months · Times ET
−0.5% · S&P 500 +0.6%
EPS of $-0.48 missed the $-0.45 estimate on $0.00 revenue (est. $10,000.00).
+4.3% · S&P 500 +0.7%
Enliven Therapeutics shares rose 14.1%, while the S&P 500 rose 0.6%.
+14.1% · S&P 500 +0.6%
EPS of $-0.38 beat the $-0.42 estimate on $0.00 revenue (est. $10,000.00).
+1.1% · S&P 500 +0.8%
Enliven Therapeutics shares rose 14.3%, while the S&P 500 rose 0.5%.
+14.3% · S&P 500 +0.5%
EPS of $-0.49 missed the $-0.37 estimate on $0.00 revenue.
+1.0% · S&P 500 −0.2%
Enliven Therapeutics closed at its highest level of the year, 226.8% above where the year started.
+2.2% · S&P 500 −0.3%
EPS of $-0.36 beat the $-0.46 estimate on $0.00 revenue.
+10.4% · S&P 500 +0.3%
Where it ended: a close of $51.55 on Nov 9, 2026. Up next: Q4 2026 earnings on Mar 2, 2027 (EPS est. $-0.47).
Nothing in the past 12 months.
All ELVN dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ELVN and SPY from Benzinga historical bars. Not investment advice.
